pHyph

Convincing efficacy and safety results 

pHyph has been shown to have an excellent medical effect. Absence of symptoms was noted in 70% of patients by day 7, and 90% had symptoms relief. A total of 50.4% of the patients treated with pHyph were clinically cured of bacterial vaginosis by day 7 which is in line with many antibiotic treatments on the market. Only 13.9% of the patients treated with pHyph experienced recurrence of bacterial vaginosis at day 35, a much lower recurrence rate than seen for patients treated with placebo, 27% and throughout the 4 month follow-up period. No patient on pHyph treatment experienced secondary vulvovaginal candidiasis infections during the 4 month follow-up period.  The vaginal tablet is safe to use and is planned to be sold over the counter, to be an easily accessible treatment option when an infection occurs. *

*Data on file

During a bacterial vaginosis, the pH of the vaginal environment is elevated compared to normal, thus favouring the infectious bacteria. An imbalance occurs in the vaginal microbioma.

The infectious bacteria begin to thrive and produces a membrane, a so called biofilm where under they are protected.

pHyph is a vaginal tablet that lowers the pH to its normal, healthy level (4.5), removes the biofilm and restores the healthy, protective vaginal microbioma, thereby reducing the risk of recurrent bacterial vaginosis.

The active substance in pHyph is a naturally occurring substance in our environment and is well documented, has GRAS status* and is used as an approved food additive.